Analysts Raise Price Targets for Four Biotech Companies

what happened

TradingView reports that the average 12-month target for Option Care Health, Inc., based on estimates from 8 analysts, increased from $29.52 to $30.03. Forecasts range from $23 to $33 per share, while the revised target represents approximately 3% downside from the Oct. 9 closing price. The “Hold” consensus is unchanged among 12 analysts: 1 Buy, 11 Holds and 0 Sells.

According to Newsmetry API, the average target for 10x Genomics, Inc. rose from $72.13 to $74.13, based on estimates from 15 analysts. Forecasts span $47 to $110, and the updated target implies about 8% downside from the Oct. 9 close. The “Buy” consensus remains in place among 18 analysts, including 6 Buys, 11 Holds and 1 Sell.

Newsmetry API says the average target for GRAIL, Inc. advanced from $116.1 to $122.1. The 10 analyst estimates range between $74 and $175, while the revised target implies approximately 13% downside from the Oct. 9 closing price. The “Buy” consensus remains across 13 analysts: 5 Buys, 7 Holds and 1 Sell.

Newsmetry API also reports that Natera, Inc.’s average target climbed from $383.89 to $387.52. Estimates from 22 analysts range from $280 to $490, and the calculation indicates roughly 3% downside. The “Buy” consensus remains among 25 analysts, with 22 Buys, 2 Holds and 1 Sell.

why it matters

The target changes reflect updated analyst expectations for companies in biotechnology and healthcare services. However, the revised targets remain below the Oct. 9 closing prices for all four stocks, while the composition of consensus ratings differs across the companies. Reference data was provided by FactSet; this information is not investment advice.

instruments